JamesLBailenMDFACS. CPI

Urology • Jeffersonville, IN

Founder of 1st Urology

Join to view full profile

Dr. Bailen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bailen's full profile

Already have an account?

Office
101 Hospital Blvd
Jeffersonville, IN 47130
Phone+1 812-282-3899

Fax+1 812-282-4173

Summary

Dr. James Bailen is an urologist in Jeffersonville, IN and is affiliated with multiple hospitals in the area, including Clark Memorial Health, Harrison County Hospital, Jewish Hospital, and Norton Women's and Children's Hospital. He received his medical degree from University of Louisville School of Medicine and has been in practice 45 years. He is experienced in prostate cancer and advanced prostate cancer.

Education & Training

University of Louisville School of MedicineResidency, Urology, 1976 - 1979
University of Miami/Jackson Health SystemInternship, Internal Medicine, 1972 - 1973
University of Louisville School of MedicineClass of 1972

Certifications & Licensure

IL State Medical License 1974 - Present
KY State Medical License 1973 - 2024
IN State Medical License 1979 - 2023
American Board of Urology Urology

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons

Clinical Trials

Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer Start of enrollment: 2009 May 01
Completed
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T Start of enrollment: 2012 Oct 01
Terminated
Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2012 Jan 01
Terminated
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT Start of enrollment: 2013 Dec 01
Terminated
Phase 1, Phase 2
PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study Start of enrollment: 2014 Sep 01
Terminated
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer Start of enrollment: 2021 May 05
Completed
Phase 3
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Start of enrollment: 2021 Mar 15
Active, not recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

6 citations
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Ronald Tutrone, Fred Saad, Daniel J George, Bertrand Tombal, James L Bailen
European Urology Oncology. 2024-08-01
2 citations
Prospective Trial of Water Vapor Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia in Subjects with a Large Prostate: 6...
Henry Woo, Richard Levin, Christopher Cantrill, Shaw Zhou, Donald Neff
European Urology Open Science. 2023-12-01
48 citations
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients wi...
David P. Dearnaley, Daniel Saltzstein, John Sylvester, Lawrence Karsh, Bryan A. Mehlhaff
European Urology. 2020-08-01

Press Mentions

Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12November 10th, 2017
Nymox Announces October 12 Symposium for Company's BPH Drug at American Urological Association MeetingSeptember 25th, 2017
First Urology of Louisville Enjoys Many "Firsts" in Technology and ResearchFebruary 10th, 2016

Professional Memberships

American College of Surgeons - ACS
Member